Capitolis Liquid Global Markets LLC Sells 65,000 Shares of Humana Inc. (NYSE:HUM)

Capitolis Liquid Global Markets LLC cut its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 71.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 25,800 shares of the insurance provider's stock after selling 65,000 shares during the period. Capitolis Liquid Global Markets LLC's holdings in Humana were worth $6,546,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of HUM. Pinnacle Wealth Management Advisory Group LLC increased its holdings in Humana by 3.6% in the 4th quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,070 shares of the insurance provider's stock worth $272,000 after buying an additional 37 shares during the period. Atlas Brown Inc. grew its stake in shares of Humana by 0.6% during the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider's stock worth $1,611,000 after purchasing an additional 38 shares during the period. Mather Group LLC. boosted its holdings in Humana by 21.0% during the fourth quarter. Mather Group LLC. now owns 236 shares of the insurance provider's stock worth $60,000 after buying an additional 41 shares in the last quarter. Capital Advisors Ltd. LLC increased its holdings in Humana by 26.1% in the fourth quarter. Capital Advisors Ltd. LLC now owns 208 shares of the insurance provider's stock valued at $53,000 after buying an additional 43 shares in the last quarter. Finally, Retirement Planning Co of New England Inc. boosted its stake in shares of Humana by 4.7% during the 4th quarter. Retirement Planning Co of New England Inc. now owns 966 shares of the insurance provider's stock worth $245,000 after acquiring an additional 43 shares in the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Price Performance

Humana stock opened at $256.94 on Tuesday. The company has a market capitalization of $31.01 billion, a PE ratio of 25.82, a price-to-earnings-growth ratio of 2.05 and a beta of 0.49. The business has a 50 day simple moving average of $266.21 and a 200 day simple moving average of $270.69. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last announced its earnings results on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, topping the consensus estimate of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analysts' expectations of $32 billion. Humana had a return on equity of 11.70% and a net margin of 1.02%. The business's revenue for the quarter was up 8.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $7.23 earnings per share. On average, sell-side analysts forecast that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Investors of record on Friday, June 27th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.38%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is currently 25.04%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on HUM shares. Cantor Fitzgerald reiterated a "neutral" rating and set a $290.00 price objective on shares of Humana in a research note on Thursday, May 1st. StockNews.com downgraded shares of Humana from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Barclays increased their price target on Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a report on Friday, April 11th. Mizuho boosted their price objective on Humana from $305.00 to $316.00 and gave the stock an "outperform" rating in a research note on Wednesday, April 9th. Finally, Robert W. Baird raised their target price on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Eighteen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $287.76.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.